Acapatamab (0.02-2 mg/kg; i.v.; days 16, 23, and 31) has antitumor activity and inhibits tumor growth in NOD/SCID mice with 22Rv-1 CRPC xenografts[1].
| Animal Model: | NOD/SCID mice with 22Rv-1 CRPC xenografts[1] |
| Dosage: | 0.02, 0.2, and 2 mg/kg |
| Administration: | Intravenous injection (days 16, 23, and 31) |
| Result: | Had antitumor activity against established CRPC tumors. |